IO Biotech (IOBT) Competitors

IO Biotech (NASDAQ:IOBT) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.

Is IOBT or NMRA more profitable?

Neumora Therapeutics' return on equity of -73.63% beat IO Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IO Biotech	N/A	-86.56%	-75.24%
Neumora Therapeutics	N/A	-73.63%	-68.97%

Do insiders and institutionals hold more shares of IOBT or NMRA?

54.8% of IO Biotech shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 2.3% of IO Biotech shares are held by insiders. Comparatively, 26.4% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in IOBT or NMRA?

Neumora Therapeutics received 4 more outperform votes than IO Biotech when rated by MarketBeat users. However, 91.67% of users gave IO Biotech an outperform vote while only 89.66% of users gave Neumora Therapeutics an outperform vote.

Company	Underperform	Outperform
IO Biotech	Outperform Votes 22 91.67%	Underperform Votes 2 8.33%
Neumora Therapeutics	Outperform Votes 26 89.66%	Underperform Votes 3 10.34%

Which has stronger earnings & valuation, IOBT or NMRA?

Neumora Therapeutics is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IO Biotech	N/A	N/A	-$86.08M	-$1.37	-0.63
Neumora Therapeutics	N/A	N/A	-$235.93M	-$1.87	-0.75

Does the media prefer IOBT or NMRA?

In the previous week, Neumora Therapeutics had 40 more articles in the media than IO Biotech. MarketBeat recorded 43 mentions for Neumora Therapeutics and 3 mentions for IO Biotech. IO Biotech's average media sentiment score of 1.19 beat Neumora Therapeutics' score of 0.14 indicating that IO Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IO Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	32 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend IOBT or NMRA?

IO Biotech currently has a consensus target price of $9.33, indicating a potential upside of 981.12%. Neumora Therapeutics has a consensus target price of $16.50, indicating a potential upside of 1,074.38%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than IO Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Neumora Therapeutics	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Which has more volatility and risk, IOBT or NMRA?

IO Biotech has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500.

Summary

Neumora Therapeutics beats IO Biotech on 8 of the 15 factors compared between the two stocks.